Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences is experiencing strong sales driven by higher demand and increased market share, particularly with its HIV portfolio, where Biktarvy now holds 52% of the U.S. market, reflecting steady growth since its launch. The company has raised its HIV growth guidance to +5% year-over-year, even in the face of anticipated challenges such as $900 million in Medicare Part D headwinds, signaling a robust foundation for future revenue. Additionally, ongoing innovations in the oncology sector, along with early-stage Immunology and Inflammation (I&I) programs, suggest significant potential for upside and reinforce Gilead's effective life-cycle management strategy.

Gilead Sciences is facing significant revenue challenges, with Trodelvy sales declining slightly quarter-over-quarter to $357 million and projections indicating a 10% decrease in cell therapy revenue for fiscal year 2025 compared to 2024. The company's flagship product, Veklury, reported revenues of $277 million, marking a substantial 60% year-over-year decline and falling short of consensus estimates, prompting a revision of FY25 revenue guidance down to $1.0 billion from an earlier expectation of $1.4 billion. Furthermore, the overall cell therapy segment underperformed with a 11% year-over-year decline to $432 million, impacted by competitive pressures from both in-class and out-of-class therapies, which raises concerns about Gilead's growth prospects amidst an increasingly competitive landscape.